Место селективных ингибиторов циклооксигеназы типа 2 в терапии острой и хронической боли

1. Вознесенский А.Г. Клиническая фармакология нестероидных
противовоспалительных средств. Волгоград, 1999.
2. Каратеев А.Е. Профилактика опасных осложнений со сторо-
ны желудочно-кишечного тракта при лечении НПВП в клиниче-
ской практике: проблемы и их решение. Клин. фарм. и тер. 2007;
16(1): 81–4.
3. Кукушкин М.Л, Решетняк В.К. Механизмы возникновения ост-
рой боли и хронических болевых синдромов. Materia Mеdica. 1997;
3(15): 5–21.
4. Лившиц Л.Я., Лобзин Ю.Я., Усин В.В. и др. Опыт изучения распро-
страненности хронических болевых синдромов. Российская на-
уч.-практ. конф. "Организация медицинской помощи больным с
болевыми синдромами": Тезисы докладов. Новосибирск, 1997;
34–5.
5. Насонов Е.Л., Каратеев А.Е. Гастропатия, связанная с приемом
нестероидных противовоспалительных препаратов. Клин. мед.
2000; 4: 4–9.
6. Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с
приемом нестероидных противовоспалительных препаратов.
Клин. мед. 2000; 3: 4–10.
7. Осипова Н.А., Абузарова Г.Р. Обозрение материалов 3-го Между-
народного конгресса Всемирного института боли (World Institute
of Pain – WIP). Боль. 2004; 1: 12–6.
8. Павленко С.С. Эпидемиология боли. Неврологич. журн. 1999;
4(1): 41–6.
9. Altman R, Luciardi HL, Muntaner J et al. Efficacy Assessment of
Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary
Syndromes Without ST-Segment Elevation. Circulation 2002; 106:
191–5.
10. Aneja A, Farkouh ME. Adverse cardiovascular effects of NSAIDs: driven
by blood pressure, or edema? Therapeutic Advances in Cardiovascular
Disease. 2008; 2(1): 53–66.
11. Basbaum AI, Fields HL. Endogenous pain control system brainstem
spinal pathways and endorphin circuitry. Neuroscience 1984; 7:
309–38.
12. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal
toxicity of rofecoxib and naproxen in patients with
rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8.
13. Bosch HC, Sigmund R, Hettich M. Efficacy and tolerability of intramuscular
and oral meloxicam in patients with acute lumbago: a
comparison with intramuscular and oral piroxicam. Curr Med Res
Opin 1997; 14: 29–38.
14. Bratlberg G, Parker MG. Thorslund M. The prevalence of pain
amongst the olders old in Sweden. Ibid: 1996; 67: 29–34.
15. Brus R, Herman ZS, Szkilnik R et al. Mediation of central
prostaglandin effects by serotoninergic neurons. Psychopharmacology
1979; 64: 116–20.
16. Cervero F, Iggo A, Molony V. The tract of Lissauer and the dorsal
root potential. J Physiol 1978; 282: 295–305.
17. Crombie IK. Epidemiology of persistent pain. Proceedings of the 8-th
World Congress on Pain: Progress in Pain Research and Management.
Vol. 8 / Eds T. S. Jensen et al. Seattle: IASP Press, 1997; 53–61.
18. Crombie IK, Croft PR et al. Epidemiology of pain. IASP Press, 1999.
19. Crook J, Rideout E, Browne G. The prevalence of pain complaints
in a general population. Pain 1984; 18: 299–314.
20. Degner F, Lanes S et al. Therapeutic roles of selective COX-2
inhibitors. Ed. Vane JR, Batting RM, 2001; part 23: 498–523.
21. Del Tacca M, Colucci R, Fornai M, Blandizzi C. Efficacy and tolerability
of meloxicam, COX2 preferential nonsteroidal antiinflammatory
drug. Clin Drug Invest 2002; 22(12): 799–818.
22. Dequeker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal
tolerability of the selective cyclooxygenase (COX)-2 inhibitor,
meloxicam, compared with piroxicam: results of the safety and efficacy
large-scale evaluation of COX-inhibiting therapies (SEL ECT)
trial in osteoarthritis. Br J Rheumatol 1998; 37: 946–51.
23. Dickenson AH, Le Bars D. Supraspinal morphine and descending
inhibitions acting on the dorsal horn of the rat. J Physiol Lond 1987;
384: 81–107.
24. Dirig DM, Yaksh TL. Hyperalgesia-associated spinal synthesis and
release of prostaglandins. In: Recent Advances in Prostaglandin,
Thromboxane and Leukotriene Research. H Sinzinger, B Samuelsson,
JR Vane, R Paoletti, P Ramwell, PY-K Wong (eds). Plenum Press, New
York, 1998; 205–8.
25. Dreiser RL, Le Parc JM, Velicitat P et al. Oral meloxicam is effective
in acute sciatica: two randomised, double-blind trials versus placebo
or diclofenac. Inflamm Res 2001; 50(Suppl. 1): S17–23.
26. Dubner R. Neural basis of persistent pain: Sensory specialisation,
sensory modulation, and neuronal plasticity. Proceedings of the 8-th
World Congress on Pain: Progress Pain Research and Management.
Vol. 8. Eds T.S.Jensen et al. Seattle: IASP Press, 1997; 243–57.
27. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of
cyclooxygenase-2. N Engl J Med 2001; 345: 433–42.
28. Fitzgerald M. Monamines and descending control of nociception.
Trends Neurosci 1986; 9: 51–2.
29. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial
infarction and sudden cardiac death in patients treated with cyclooxygenase
2 selective and non-selective non-steroidal anti-inflammatory
drugs: nested case-control study. Lancet 2005; 365: 475–81.
30. Gureje O, Simon GE, Van Korff M. A cross-national study of the
course of persistent pain in primary care. Pain 2001; 92: 195–200.
31. Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability
of meloxicam compared to diclofenac in osteoarthritis patients..
Br J Rheumatol 1998; 37: 937–45.
32. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307–14.
33. Hefferan MP, Carter P, Haley M et al. Spinal nerve injury activates
prostaglandin synthesis in the spinal cord that contributes to early
maintenance of tactile allodynia. Pain 2003; 101(1–2): 139–47.
34. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in
patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal
anti-inflammatory drugs: population based nested casecontrol
analysis. Br Med J 2005; 330(11): 1366–72.
35. Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles
of prostaglandins in pain and their interactions with novel neuropeptides
nociceptin and nocistatin. Neurosci Res 2001; 41(4):
299–332.
36. Juan H, Lembeck F, Seewann S et al. Nociceptor stimulation and
PGE release by capsaicin. Naunyn-Schmiedeberg's Archives of Pharmacology
1980; 312(2): 139–43.
37. Kirschenbaum A, Liotta DR, Yao S et al. Immunohistochemical
localization of cyclooxygenase-1 and cyclooxygenase-2 in the
human fetal and adult male reproductive tracts. J Clin Endocrinol
Metab 2000; 85: 3436–41.
38. Lipscomb GR, Wallis N, Armstrong G et al. Gastrointestinal tolerability
of meloxicam and piroxicam: a double-blind placebo-controlled
study. Br J Clin Pharmacol 1998; 46: 133–7.
39. Ma W, Eisenach J. Cyclooxygenase 2 in infiltrating inflammatory
cells in injured nerve is universally up-regulated following various
types of peripheral nerve injury. Neuroscience 2003; 121: 691–704.
40. Martin RM, Biswas P, Mann RD. The incidence of adverse events
and risk factors for upper gastrointestinal disorders associated with
meloxicam use amongst 19 087 patients in general practice in England:
cohort study. Br J Clin Pharmacol 2000; 50: 35–42.
41. Maslinska D, Kaliszek A, Opertowska J et al. Constitutive expression
of cyclooxygenase-2 (COX-2) in developing brain: A choriod
plexus in human fetuses. Folia Neuropathol 1999; 37: 287–91.
42. McAdam BF, Catella-Lawson F, Mardini IA et al. Systemic biosynthesis
of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology
of a selective inhibitor of COX-2. Proc Natl Acad Sci USA
1999; 96: 272–7.
43. Mdntyselka P, Kumpusalo E, Ahonen R et al. Pain as a reason to visit
the doctor: a study in Finnish primary health care. Ibid: 89: 175–80.
44. Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965;
150: 971–8.
45. Narumiya S, Ogorochi T, Nakao K et al. Prostaglandin D2 in the rat
brain, spinal cord and the pituitary: basal level and regional distribution.
Life Science 1982; 31: 2093–103.
46. Oliveira MCG, Pelegrini-da-Silva A, Parada CA et al. 5-HT acts on
nociceptive primary afferents through an indirect mechanism to induce
hyperalgesia in the subcutaneous tissue. Neuroscience 2007; 145(2):
708–14.
47. Ott E, Nussmeier NA, Duke PC et al. Efficacy and safety of the cyclooxygenase
2 inhibitors parecoxib and valdecoxib in patients undergoing
coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125(6):
1481–92.
48. Page J, Henry D. Consumption of NSAIDs and the development of congestive
heart failure in elderly patients: an under-recognized public
health problem. Arch Intern Med 2000; 160: 777–84.
49. Rainsford KD. Screening for adverse effects fr om anti-inflammatory
drugs. In: Brooks PM, Day RO, Williams K, Graham G, eds. Basis for variability
of response to anti-rheumatic drugs Basel: Birkhaeuser, 1988;
31–44.
50. Ray WA, Stein CM, Hall K et al. Non-steroidal anti-inflammatory drugs
and risk of serious coronary heart disease: an observational cohort study.
Lancet 2002; 359(9301): 118–23.
51. Ruan HZ, Li XC, Cai WQ. Effect of 5-HT on pain modulation of substance
P in spinal cord of rats. Zhongguo Yao Li Xue Bao 1995; 16(6):
512–6.
52. Samad TA, Moore KA, Sapirstein A et al. Interleukin-1beta-mediated
induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity.
Nature 2001; 410: 471–5.
53. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory
drugs. Kidney Int 1993; 44: 643.
54. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a metaanalysis
and systematic review of randomized controlled trials. Am J Med
1999; 107(Suppl.6A): 48–54S.
55. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci 2002; 5(pp. l):
1062–7.
56. Seibart K, Zhang Y, Leahy K et al. Pharmacological and biochemical
demonstration of the role of cyclooxygenase-2 in inflammation and pain.
Proc. Nat Acad Sci USA 1994; 91: 12013–7.
57. Simon LS. Historical Review: Rationale for Use and the Class-Effect
Question. In: The Pulse of Current Cardiovascular Concern: Anti-inflammatory
Medications. Accessed 30/12/2004.
58. Singh G, Triadafilopoulos G. Meloxicam has a low risk of serious gastrointestinal
complications: pooled analysis of 27 039 patients: the results
of the IMPROVE trial (abstract). European Congress of Rheumatology,
Prague, 2001 Jun 13–6.
59. Smith WL, Dewitt DL, Garavito RM. Cyclooxygenases: Structural, cellular,
and molecular biology. Ann Rev Biochem 2000; 69: 145–82.
60. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H
synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271:
33157–60.
61. Soberman RJ, Christmas P. The organization and consequences of
eicosanoid signaling. J Clin Invest 2003; 111(8): 1107–13.
62. Staerkel P, Horsmans Y. Meloxicam-induced liver toxicity. Acta Gastroenterol
Belg 1999; 62: 255–6.
63. Stucky ChL, Gold MS, Zhang X. Mechanisms of pain. PNAS 2001;
98(21): 11845–6.
64. Topol EJ. Arthritis medicines and cardiovascular events – "house of
coxibs". JAMA 2005; 293: 366–8.
65. Turnbach ME, Spraggins DS, Randich A. Spinal administration of
prostaglandin E2 or prostaglandin F2 alpha primarily produces
mechanical hyperalgesia that is mediated by nociceptive specific spinal
dorsal horn neurons.. Pain 2002; 97(1–2): 33–45.
66. Unruch M. Gender variations in clinical pain experience. Pain 1996;
1: 123–61.
67. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action
for aspirin-like drugs. Nature (New Biol) 1971; 231: 232–5.
68. Verhaak PFM, Kerssens JJ, Dekker J et al. Prevalence of chronic benign
pain disorder among adults: a revier of the literature. Ibid: 1998; 77:
231–9.
69. Vidal L, Kneer W, Baturone M et al. Meloxicam in acute episodes of
soft-tissue rheumatism of the shoulder. Inflamm Res 2001; 50(Suppl. 1):
S24–9.
70. Wang HQ, Smart RC. Overexpression of protein kinase C- in the epidermis
of trans-genic mice results in striking alterations in phorbol-ester
induced inflammation and COX-2, MIP-2, and TNF- expression but not
tumor promotion. J Cell Sci 1999; 112: 3497–506.
71. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): Filling in the gaps
toward a COX continuum? PNAS 2002; 99(21): 13371–3.
72. Wasner G. Interaction between histamine-induced itch and experimental
muscle pain. Eur J Pain 2004; 8(Is.3): 179–85.
73. Whelton A, Fort JG, Puma JA et al. Cyclooxygenase-2 specific inhibitors
and cardiorenal function: a randomized, controlled trial of celecoxib and
rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8:
85–95.
74. Wolfe M, Lichtenstein DR, Sinhg G. Gastrointestinal toxicity of nonsteroidal
anti-inflammatory drugs. N Engl J Med 1999; 24: 1888–99.
75. Yang T, Singh I, Pham H et al. Regulation of cyclooxygenase expression
in the kidney by dietary salt intake. Am J Physiol 1998; 264: F481–9.